Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;34(5):705-8.
doi: 10.1007/s00296-013-2758-4. Epub 2013 May 1.

Distribution of HLA-DRβ1 alleles among well-characterized rheumatoid arthritis patients from Western India

Affiliations

Distribution of HLA-DRβ1 alleles among well-characterized rheumatoid arthritis patients from Western India

Devaraj J Prasannavar et al. Rheumatol Int. 2014 May.

Abstract

An association between human leukocyte antigen-DRβ1*04 and rheumatoid arthritis (RA) has been known for more than 25 years. It has been observed in many different populations, and it accounts for approximately one-third of the genetic component of RA susceptibility. Our aim was to study the distribution of HLA-DRβ1 alleles in well-characterized RA patients from Western India. Polymerase chain reaction-based sequence-specific oligonucleotide probing (PCR-SSOP) technique was used to identify HLA-DRβ1 alleles among 80 clinically well-defined patients and 90 normal controls from same ethnicity. A significant increase in the frequency of DRβ1*04 was observed among RA patients (PF% 30 vs. 7.7, OR 4.959, p value 0.00018), whereas DRβ1*03 and *14 were significantly decreased among patients when compared with controls (DRβ1*03, PF% 8.75 vs. 26.6, OR 0.2637, p value 0.00253; DRβ1*14, PF% 17.5 vs. 30.0, OR 0.4949, p value 0.05722). Our results suggest that DRβ1*04 was strongly associated with well-characterized RA patients from Western India, whereas DRβ1*03 and *14 may be protective alleles for RA. The identification of susceptible allele in patients with RA may help physician to make early decisions regarding initiation of early intensive therapy with disease modifying anti-rheumatic drugs and biological agents to decrease disability in RA patients.

PubMed Disclaimer

Similar articles

References

    1. Autoimmune Dis. 2012;2012:569728 - PubMed
    1. Arthritis Rheum. 1987 Nov;30(11):1205-13 - PubMed
    1. Hum Immunol. 1996 Mar;46(1):35-41 - PubMed
    1. J Korean Med Sci. 2007 Dec;22(6):973-80 - PubMed
    1. Ann Saudi Med. 2011 Mar-Apr;31(2):171-3 - PubMed

LinkOut - more resources